Annual CFO
-$156.32 M
+$27.62 M+15.02%
31 December 2023
Summary:
Adaptive Biotechnologies annual cash flow from operations is currently -$156.32 million, with the most recent change of +$27.62 million (+15.02%) on 31 December 2023. During the last 3 years, it has fallen by -$6.64 million (-4.44%). ADPT annual CFO is now -176.11% below its all-time high of $205.40 million, reached on 31 December 2019.ADPT Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$27.07 M
-$9.76 M-56.42%
30 September 2024
Summary:
Adaptive Biotechnologies quarterly cash flow from operations is currently -$27.07 million, with the most recent change of -$9.76 million (-56.42%) on 30 September 2024. Over the past year, it has increased by +$19.62 million (+42.03%). ADPT quarterly CFO is now -109.73% below its all-time high of $278.30 million, reached on 31 March 2019.ADPT Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$109.65 M
+$19.62 M+15.18%
30 September 2024
Summary:
Adaptive Biotechnologies TTM cash flow from operations is currently -$109.65 million, with the most recent change of +$19.62 million (+15.18%) on 30 September 2024. Over the past year, it has increased by +$49.76 million (+31.21%). ADPT TTM CFO is now -143.49% below its all-time high of $252.14 million, reached on 31 March 2019.ADPT TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADPT Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +15.0% | +42.0% | +31.2% |
| 3 y3 years | -4.4% | +37.7% | +38.6% |
| 5 y5 years | -384.6% | +10.2% | -148.3% |
ADPT Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -4.4% | +18.9% | -56.4% | +58.0% | at high | +47.5% |
| 5 y | 5 years | -176.1% | +18.9% | -56.4% | +58.0% | -148.3% | +47.5% |
| alltime | all time | -176.1% | +18.9% | -109.7% | +58.0% | -143.5% | +47.5% |
Adaptive Biotechnologies Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$27.07 M(+56.4%) | -$109.65 M(-15.2%) |
| June 2024 | - | -$17.30 M(-54.9%) | -$129.27 M(-4.6%) |
| Mar 2024 | - | -$38.35 M(+42.4%) | -$135.53 M(-13.3%) |
| Dec 2023 | -$156.32 M(-15.0%) | -$26.93 M(-42.3%) | -$156.32 M(-1.9%) |
| Sept 2023 | - | -$46.68 M(+98.2%) | -$159.41 M(+2.8%) |
| June 2023 | - | -$23.56 M(-60.2%) | -$155.13 M(-13.2%) |
| Mar 2023 | - | -$59.15 M(+97.0%) | -$178.64 M(-2.9%) |
| Dec 2022 | -$183.94 M(-4.6%) | -$30.02 M(-29.2%) | -$183.94 M(-11.5%) |
| Sept 2022 | - | -$42.41 M(-9.9%) | -$207.75 M(-0.5%) |
| June 2022 | - | -$47.06 M(-27.0%) | -$208.79 M(+5.0%) |
| Mar 2022 | - | -$64.45 M(+19.7%) | -$198.94 M(+3.2%) |
| Dec 2021 | -$192.73 M | -$53.83 M(+23.9%) | -$192.73 M(+7.8%) |
| Sept 2021 | - | -$43.44 M(+16.7%) | -$178.75 M(-2.0%) |
| June 2021 | - | -$37.21 M(-36.1%) | -$182.46 M(+3.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$58.24 M(+46.2%) | -$176.32 M(+17.8%) |
| Dec 2020 | -$149.68 M(-172.9%) | -$39.84 M(-15.5%) | -$149.68 M(+9.6%) |
| Sept 2020 | - | -$47.16 M(+51.7%) | -$136.63 M(+14.2%) |
| June 2020 | - | -$31.08 M(-1.7%) | -$119.61 M(+14.5%) |
| Mar 2020 | - | -$31.61 M(+18.0%) | -$104.50 M(-150.9%) |
| Dec 2019 | $205.40 M(-736.7%) | -$26.79 M(-11.1%) | $205.40 M(-9.4%) |
| Sept 2019 | - | -$30.14 M(+88.7%) | $226.78 M(-7.5%) |
| June 2019 | - | -$15.97 M(-105.7%) | $245.24 M(-2.7%) |
| Mar 2019 | - | $278.30 M(-5244.2%) | $252.14 M(-881.6%) |
| Dec 2018 | -$32.26 M(-7.5%) | -$5.41 M(-53.7%) | -$32.26 M(+20.1%) |
| Sept 2018 | - | -$11.69 M(+28.9%) | -$26.85 M(+77.1%) |
| June 2018 | - | -$9.07 M(+48.7%) | -$15.16 M(+148.7%) |
| Mar 2018 | - | -$6.10 M | -$6.10 M |
| Dec 2017 | -$34.86 M | - | - |
FAQ
- What is Adaptive Biotechnologies annual cash flow from operations?
- What is the all time high annual CFO for Adaptive Biotechnologies?
- What is Adaptive Biotechnologies annual CFO year-on-year change?
- What is Adaptive Biotechnologies quarterly cash flow from operations?
- What is the all time high quarterly CFO for Adaptive Biotechnologies?
- What is Adaptive Biotechnologies quarterly CFO year-on-year change?
- What is Adaptive Biotechnologies TTM cash flow from operations?
- What is the all time high TTM CFO for Adaptive Biotechnologies?
- What is Adaptive Biotechnologies TTM CFO year-on-year change?
What is Adaptive Biotechnologies annual cash flow from operations?
The current annual CFO of ADPT is -$156.32 M
What is the all time high annual CFO for Adaptive Biotechnologies?
Adaptive Biotechnologies all-time high annual cash flow from operations is $205.40 M
What is Adaptive Biotechnologies annual CFO year-on-year change?
Over the past year, ADPT annual cash flow from operations has changed by +$27.62 M (+15.02%)
What is Adaptive Biotechnologies quarterly cash flow from operations?
The current quarterly CFO of ADPT is -$27.07 M
What is the all time high quarterly CFO for Adaptive Biotechnologies?
Adaptive Biotechnologies all-time high quarterly cash flow from operations is $278.30 M
What is Adaptive Biotechnologies quarterly CFO year-on-year change?
Over the past year, ADPT quarterly cash flow from operations has changed by +$19.62 M (+42.03%)
What is Adaptive Biotechnologies TTM cash flow from operations?
The current TTM CFO of ADPT is -$109.65 M
What is the all time high TTM CFO for Adaptive Biotechnologies?
Adaptive Biotechnologies all-time high TTM cash flow from operations is $252.14 M
What is Adaptive Biotechnologies TTM CFO year-on-year change?
Over the past year, ADPT TTM cash flow from operations has changed by +$49.76 M (+31.21%)